A gene therapy (MR-146) for stage 1 or 2 neurotrophic keratopathy

You may qualify if

• Be ≥18 years or greater of age at Visit 1.
• Have a diagnosis of Stage 1 or Stage 2 in the study eye for Part 1 or Stage 2 NK in the study eye for Part 2.
• Willing and able to participate in and attend to all study visits over the course of 12-14 months

You can't join if

• Have Stage 2 NK affecting both eyes, or Stage 3 NK in either eye.
• Any active ocular infections or active ocular inflammation not related to NK in the affected eye.
• Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study
• Have monocular vision in the study eye or have BSCVA less than 20/100 in the fellow eye.
• Any neurodegenerative disease (example: Parkinson's, Alzheimer's, Multiple Sclerosis, etc)
• Uncontrolled glaucoma in either eye.
• Any plan to use therapeutic contact lenses.
• Anyone pregnant, nursing, or planning to become pregnant within 3 months of participating in the study.
• History of incisional conjunctival surgery in the study eye.
• History of any ocular surgery in the affected eye within the last 3 months
• Botox use in the face or orbital area and/or lacrimal gland within the last 6 months.